# Neoadjuvant L19IL2/L19TNF- Pivotal Study

Source: https://onco.cc/trials/nct02938299/  
OnCo record `nct02938299` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of L19IL2 + L19TNF in melanoma, run by Philogen S.p.A., active and no longer recruiting.

## Summary

Neoadjuvant L19IL2/L19TNF- Pivotal Study is a phase 3 interventional study registered as NCT02938299 by Philogen S.p.A., with 214 participants enrolled, started 2016-07-01 and due to reach its primary completion in 2024-10. Interventions recorded: L19IL2 + L19TNF and Surgery.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02938299
- Phase: 3
- Setting: A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
- Sponsor: Philogen S.p.A.
- Enrolled: 214

## Sources

- ClinicalTrials.gov NCT02938299: https://clinicaltrials.gov/study/NCT02938299

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct02938299.json